Synthesis of EB-TATE
TATE-SH (1 eq) was dissolved in 10% (v/v) Dimethyl sulfoxide (DMSO) and 90% of 0.1%
(w/v) Na-ascorbate in PBS and mixed with 1 eq of EB derivative dissolved in 0.1% Naascorbate (w/v) in PBS to a total volume of 1-2 mL. The reaction was stirred for 2 h at room temperature and purified by HPLC to give EB-TATE in a chemical purity >95% and a yield of 
Albumin binding assay
In vitro albumin binding affinity of EB-TATE was evaluated by competitive study against 86 Y-EB-TATE using streptavidin agarose beads (Thermo Fisher Scientific) and biotinylated human serum albumin (Protein Mods). 200 µL of beads slurry were washed five times with PBS by centrifuge and then resuspend in PBS and mixed with 600 µL biotinylated-HSA (1 mg/mL, 3-molar excess) for 1 h at room temperature. Then the mixture was extensively washed with PBS to remove excess of biotinylated-HSA. Next, the labeled beads were incubated with radiolabeled 7.4 KBq 86 Y-EB-TATE and increasing concentrations (1 nM-100 µM) of unlabeled EB-TATE for 1.5 h at room temperature in a 96-well membrane plate. After the incubation, the plate was washed several times with PBS and the radioactivity bound to the beads was measured using a gamma-counter. Each time point was measured in triplicate.
Y-EB-TATE Biodistribution
1.85 MBq of 90 Y-EB-TATE was intravenous injected to HCT116/SSTR2 tumor bearing mice. At days 1 (n = 5), 4 (n = 6), 7 (n = 6) and 12 (n = 7) post-injection, mice were sacrificed and tumor, heart, lung, liver, spleen, intestine, kidney, muscle, bone and blood were collected.
The tissues were minced, weighed and dissolve in 1-1. 
In vivo stability
Mice bearing HCT116/SSTR2 tumors were each injected with 1.85 MBq of 90 Y-EB-TATE, tumors were collected at different time points post-injection, minced, and dissolved in 50 µL of CH3CN:CH3OH (1:1). The slurry solution was centrifuge for 1-2 min at 10,000 rpm.
An aliquot was taken and analyzed by iTLC plate, as described in the radiochemistry methodology section above. 
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